Onychomatricoma (OM) is a rare benign tumour of the nail matrix characterized by specific clinical and histologic features. The main clinical signs are thickening of the nail plate, xanthonychia, overcurvature of the nail plate, and multiple splinter haemorrhages. The diagnosis is based on clinical, radiological and histopathological findings. Histologically, the tumour is characterized by filiform epithelial projections. The objective of this study is to present the first reported Tunisian case of OM, focusing on the contribution of magnetic resonance imaging to the diagnosis of OM. A review on the subject is also presented.

1.
Baran
R
,
Kint
A
.
Onychomatrixoma. Filamentous tufted tumour in the matrix of a funnel-shaped nail: a new entity (report of three cases)
.
Br J Dermatol
.
1992
May
;
126
(
5
):
510
5
.
[PubMed]
0007-0963
2.
Haneke
E
,
Fränken
J
.
Onychomatricoma
.
Dermatol Surg
.
1995
Nov
;
21
(
11
):
984
7
.
[PubMed]
1076-0512
3.
Richert
B
,
Lecerf
P
,
Caucanas
M
,
André
J
.
Nail tumors
.
Clin Dermatol
.
2013
Sep-Oct
;
31
(
5
):
602
17
.
[PubMed]
0738-081X
4.
Pommepuy
I
,
Roblet
D
,
Blaise
S
,
Delage-Corre
M
,
Bonnetblanc
JM
,
Fayol
J
, et al
L’onychomatricome, une lésion rare de l’ongle
.
Ann Pathol
.
2004
Sep
;
24
(
4
):
368
70
.
[PubMed]
0242-6498
5.
Di Chiacchio
N
,
Tavares
GT
,
Tosti
A
,
Di Chiacchio
NG
,
Di Santis
E
,
Alvarenga
L
, et al
Onychomatricoma: epidemiological and clinical findings in a large series of 30 cases
.
Br J Dermatol
.
2015
Nov
;
173
(
5
):
1305
7
.
[PubMed]
0007-0963
6.
Piraccini
BM
,
Antonucci
A
,
Rech
G
,
Starace
M
,
Misciali
C
,
Tosti
A
.
Onychomatricoma: first description in a child
.
Pediatr Dermatol
.
2007
Jan-Feb
;
24
(
1
):
46
8
.
[PubMed]
0736-8046
7.
Wynes
J
,
Wanat
KA
,
Huen
A
,
Mlodzienski
AJ
,
Rubin
AI
.
Pigmented onychomatricoma: A rare pigmented nail unit tumor presenting as longitudinal melanonychia that has potential for misdiagnosis as melanoma
.
J Foot Ankle Surg
.
2015
Jul-Aug
;
54
(
4
):
723
5
.
[PubMed]
1067-2516
8.
Alves Luce
MC
,
Lobo Jardim
MM
,
Kakizaki
P
,
Sakai Valente
NY
.
Giant onychomatricoma
.
An Bras Dermatol
.
2018
;
93
(
1
):
154
62
.
[PubMed]
0365-0596
9.
Perrin
C
,
Baran
R
.
Onychomatricoma with dorsal pterygium: pathogenic mechanisms in 3 cases
.
J Am Acad Dermatol
.
2008
Dec
;
59
(
6
):
990
4
.
[PubMed]
0190-9622
10.
Perrin
C
,
Goettmann
S
,
Baran
R
.
Onychomatricoma: clinical and histopathologic findings in 12 cases
.
J Am Acad Dermatol
.
1998
Oct
;
39
(
4 Pt 1
):
560
4
.
[PubMed]
0190-9622
11.
Joo
HJ
,
Kim
MR
,
Cho
BK
,
Yoo
G
,
Park
HJ
.
Onychomatricoma: A Rare Tumor of Nail Matrix
.
Ann Dermatol
.
2016
Apr
;
28
(
2
):
237
41
.
[PubMed]
1013-9087
12.
Lee
DY
,
Lee
JH
.
Use of dermoscopy to identify nail plate cavities as a clinical diagnostic clue for onychomatricoma
.
Int J Dermatol
.
2016
Feb
;
55
(
2
):
e108
10
.
[PubMed]
0011-9059
13.
Rushing
CJ
,
Ivankiv
R
,
Bullock
NM
,
Rogers
DE
,
Spinner
SM
.
Onychomatricoma: A rare and potentially underreported tumor of the nail matrix
.
J Foot Ankle Surg
.
2017
Sep - Oct
;
56
(
5
):
1095
8
.
[PubMed]
1067-2516
14.
Soto
R
,
Wortsman
X
,
Corredoira
Y
.
Onychomatricoma: clinical and sonographic findings
.
Arch Dermatol
.
2009
Dec
;
145
(
12
):
1461
2
.
[PubMed]
0003-987X
15.
Cinotti
E
,
Veronesi
G
,
Labeille
B
,
Cambazard
F
,
Piraccini
BM
,
Dika
E
, et al
Imaging technique for the diagnosis of onychomatricoma
.
J Eur Acad Dermatol Venereol
.
2018
Nov
;
32
(
11
):
1874
8
.
[PubMed]
0926-9959
16.
Goettmann
S
,
Drape
JL
,
Idy-Peretti
I
,
Bittoun
J
,
Thelen
P
,
Arrive
L
, et al
Magnetic resonance imaging: a new tool in the diagnosis of tumours of the nail apparatus
.
Br J Dermatol
.
1994
Jun
;
130
(
6
):
701
10
.
[PubMed]
0007-0963
17.
Sanchez
M
,
Hu
S
,
Miteva
M
,
Tosti
A
.
Onychomatricoma has channel-like structures on in vivo reflectance confocal microscopy
.
J Eur Acad Dermatol Venereol
.
2014
Nov
;
28
(
11
):
1560
2
.
[PubMed]
0926-9959
18.
Miteva
M
,
de Farias
DC
,
Zaiac
M
,
Romanelli
P
,
Tosti
A
.
Nail clipping diagnosis of onychomatricoma
.
Arch Dermatol
.
2011
Sep
;
147
(
9
):
1117
8
.
[PubMed]
0003-987X
19.
Coutellier
A
,
Théate
I
,
Vanhooteghem
O
.
unusual localisation for onychomatricoma on the 5th toenail: A case report and review of the literature
.
Case Rep Dermatol Med
.
2016
;
2016
:
1853495
.
[PubMed]
2090-6463
20.
Gutiérrez García-Rodrigo
C
,
Velasco Tamaríz
V
,
Prieto Barrios
M
,
Rodríguez-Peralto
JL
,
García Bracamonte
B
.
Diving under nail plate
.
Skin Appendage Disord
.
2018
Apr
;
4
(
2
):
125
7
.
[PubMed]
2296-9195
21.
Reserva
JL
,
Ruben
BS
,
Venna
SS
.
Asymptomatic longitudinal pachyxanthonychia of the fingernail
.
Skin Appendage Disord
.
2017
Mar
;
3
(
1
):
32
5
.
[PubMed]
2296-9195
22.
Prevezas
C
,
Triantafyllopoulou
I
,
Belyayeva
H
,
Sgouros
D
,
Konstantoudakis
S
,
Panayiotides
I
, et al
Giant Onychomatricoma of the great toenail: case report and review focusing on less common variants
.
Skin Appendage Disord
.
2016
May
;
1
(
4
):
202
8
.
[PubMed]
2296-9195
23.
Perrin
C
,
Baran
R
,
Balaguer
T
,
Chignon-Sicard
B
,
Cannata
GE
,
Petrella
T
, et al
Onychomatricoma: new clinical and histological features. A review of 19 tumors
.
Am J Dermatopathol
.
2010
Feb
;
32
(
1
):
1
8
.
[PubMed]
0193-1091
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.